MedPath

Oral Alfacalcidol and Coronary Artery Calcification in Predialysis Chronic Kidney Disease

Phase 2
Conditions
Vascular Calcification
Interventions
Registration Number
NCT01364688
Lead Sponsor
Ramathibodi Hospital
Brief Summary

Active vitamin D at therapeutic dose may prevent vascular calcification but in supraphysiologic dose may precipitate it.

Detailed Description

Active vitamin D compound is used frequently in the treatment of hyperparathyroidism in chronic kidney disease. Recent evidence from animal studies suggested that low dose of active vitamin D may be protective against vascular calcification, whereas high dose could precipitate it. The present study will examine the effect of low dose oral alfacalcidol on coronary artery calcification in predialysis chronic kidney disease patients with hyperparathyroidism.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
80
Inclusion Criteria
  • Predialysis chronic kidney disease with GFR < 90 mL/min/1.73m2
  • PTH above the upper limit of normal
  • serum calcium and phosphate below the upper limit of normal
Exclusion Criteria
  • changes in GFR>15% during the past 3 months
  • receive elemental calcium>500 mg/day
  • currently taking active vitamin D, oral calcium with elemental calcium>500 mg/day or bisphosphonate

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Treatmentoral alfacalcidoloral alfacalcidol
Controlno drugNo drug
Primary Outcome Measures
NameTimeMethod
Change in Coronary Artery Calcification6 months and 12 months
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Faculty of Medicine, Ramathibodi Hospital, Mahidol University

🇹🇭

Phayathai, Bangkok, Thailand

© Copyright 2025. All Rights Reserved by MedPath